For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 31-November 6, 2026
Drug pricing and PBMs Medicare’s second round of negotiated prices starts in two months. On January 1, negotiated prices for…
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Search Posts
Blog
New legislation seeks to shuffle the deck chairs on the sinking No Surprises Act
On October 8, Rep. Frank Pallone (D-NJ) introduced the Lower Premiums, Faster Payments Act as a fix for the disastrous No Surprises Act (NSA).
Blog
This week in health care policy: September 28 – October 2, 2026
Drug pricing CMS finalizes GLOBE pilot. On September 30, CMS finalized the Global Benchmark for Efficient Drug Pricing model, a…
Blog
This week in health care policy: September 21–25, 2026
Innovation watch FDA approves the first treatment for Sanfilippo syndrome. On September 17, the FDA approved Ultragenyx’s Fayuvi, a one-time…
Blog
How The No Surprises Act worsened the problem of surprise bills
Next week, Sen. Bill Cassidy (R-LA) will convene a roundtable to discuss adjustments to the 2020 No Surprises Act, which has come under…
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
News Release
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…